MedTrace Logo

Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection

NCT05043129 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-09-17

No results posted yet for this study

Summary

On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19). People infected with human immunodeficiency virus (HIV) are affected by their underlying diseases and are listed by the World Health Organization (WHO) as a high-risk population of SARS-CoV-2 infection.To evaluate the safety and effectiveness of COVID-19 vaccine in those patients with human immunodeficiency virus infection , and to guide the COVID-19 vaccination more scientifically, reasonably and effectively, this study was carried out.

Conditions

  • HIV Infections
  • Covid19

Interventions

BIOLOGICAL

Biological/Vaccine: SARS-COV-2 VACCINE

The antibody titer and adverse reactions were observed.

Sponsors & Collaborators

  • The Second Affiliated Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • Hong Ren, PHD · The Second Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-04
Primary Completion
2022-03-01
Completion
2022-09-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043129 on ClinicalTrials.gov